The global dyspnea treatment market, valued at USD 5.90 billion in 2022, is expected to experience robust growth, projected to reach approximately USD 12.3 billion by 2033 with a CAGR of 6.9% from ...
Patients were randomly assigned in a 1:1 ratio to receive either intravenous (IV) serelaxin 30 μg/kg per day (n = 3,274) or placebo (n = 3,271). Dyspnea at rest or with minimal exertion Pulmonary ...
# report_head contains the column report_no, a unique identifier for each report # the report_head dataframe contain report_no, a unique indentifier for each report ...
[11] Dyspnea resulting from complications due to an end-stage disease is often treated with a nebulized opioid. Dyspnea can cause great discomfort and worry to patients, and it is difficult to ...
In addition to pharmacologic interventions and oxygen, there are a number of nonpharmacologic strategies that can be beneficial in the management of dyspnea. By changing a patient's physical ...
These results are remarkable in that the patient, though quite normal at rest, was now so incapacitated that walking was difficult and dyspnea was considerable with slight exertion. The pulse ...
Dyspnea was precipitated by running, swimming for long distances or moving heavy objects ... The above pattern was consistent with a moderate restrictive defect with severely reduced diffusion ...
You can get some of the best smartphones available on AT&T, including the likes of Apple's iPhone 16 Pro, Samsung Galaxy 24 Ultra and Google's Pixel 9 series. AT&T also offers a great lineup of ...